Try our mobile app

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Danaher Corporation designs, manufactures, and markets professional, medical, industrial and commercial products, and services in the sectors of test and measurement, environmental, life sciences, dental, and industrial technologies.
Website: danaher.com


  • Bad financial results growth rate -2.5% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-3.1%)
  • Dividend yield for the last twelve months 0.6%
  • Free cash flow yield -1.5% (LTM)
  • Share price is 13.1% higher than minimum and 34.7% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (28.5x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $249.0 mln (-0.174% of cap.)

Key Financials (Download financials)

Ticker: DHR
Share price, USD:  (-0.6%)197.54
year average price 230.79  


year start price 244.51 2024-07-01

max close price 280.76 2024-08-01

min close price 174.64 2025-04-08

current price 197.54 2025-07-01
Common stocks: 727 076 992

Dividend Yield:  0.6%
FCF Yield LTM: -1.5%
EV / LTM EBITDA: 28.5x
EV / EBITDA annualized: 27.3x
Last revenue growth (y/y):  -0.9%
Last growth of EBITDA (y/y):  -4.0%
Historical revenue growth:  +0.9%
Historical growth of EBITDA:  -7.1%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 143 627
Net Debt ($m): 14 492
EV (Enterprise Value): 158 119
EBITDA LTM ($m): 5 548
EV / LTM EBITDA: 28.5x
Price to Book: 2.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-06-30seekingalpha.com

Danaher: Biotech Momentum, Cost Cuts And Valuation Re-Rating Should Drive Upside

2025-06-27zacks.com

CVS vs. DHR: Which Stock Is the Better Value Option?

2025-06-27prnewswire.com

Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

2025-06-27prnewswire.com

Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

2025-06-20zacks.com

Why Danaher (DHR) is a Top Growth Stock for the Long-Term

2025-06-19seekingalpha.com

Danaher: High Capex And Low Debt Despite Trump Legislation

2025-06-17prnewswire.com

Danaher Schedules Second Quarter 2025 Earnings Conference Call

2025-06-11zacks.com

CVS vs. DHR: Which Stock Should Value Investors Buy Now?

2025-05-26zacks.com

CVS or DHR: Which Is the Better Value Stock Right Now?

2025-05-22zacks.com

Why Is Danaher (DHR) Down 4.8% Since Last Earnings Report?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data